The Medical Xchange

  • Edit profile
  • Logout
Login    Register

oncology

15th Annual Scientific Meeting of the Society for Neuro-Oncology (SNO)

November 18-21, 2010 / Montreal, Quebec

Anti-Inflammatory Agents May Reduce Glioma Risk

Montreal – The concept of chemoprevention suggests cancer or its progression may be prevented through administration of drugs or consumption of certain foods or phytochemicals. An award-winning study at this year’s SNO meeting determined that chemoprevention of brain tumours may be possible with statins and NSAIDS

There is rapidly expanding interest in preventing cancer or its progression in individuals at risk – or even in the general population – through administration of drugs or consumption of certain foods or phytochemicals. As part of this line of inquiry, some researchers are focusing on the role of inflammation in cancer development – especially, attempting to clarify the likely numerous mechanisms by which inflammation may promote tumour development or persistence, and the potential for medications that reduce inflammation to reduce cancer risk. Acetylsalicylic acid (aspirin) and other non-steroidal anti-inflammatory drugs (NSAIDs), for example, have been shown in numerous studies to reduce the risk of colorectal and possibly other cancers, although candidate selection and optimal dosing require further study. Anti-inflammatory mechanisms also may explain some of the beneficial effects of the statin class of medications.

Pilot Study

Chemoprevention of devastating brain tumours with medication with anti-inflammatory and/or immunomodulatory effects may be achievable.

Presented at this year’s SNO meeting, according to a pilot case-control by Dr. Rose Lai et al. from Columbia University, New York and the University of California, San Francisco, chemoprevention of devastating brain tumours with medication with anti-inflammatory and/or immunomodulatory effects may be achievable.

Through evaluation of 200 cases and 400 controls, the researchers determined that taking a statin for more than 6 months reduced the risk of a malignant glioma by 20% (OR = 0.8, 95% CI 0.6, 1.1). The most notable effect was seen with simvastatin, which crosses the bloodbrain barrier most effectively than other statins: it led to a significant 50% reduction in risk (OR = 0.5, 95% CI 0.3, 0.8). Increasing the duration of use had a stronger protective effect (trend test P < 0.01).

In a separate but related study, the investigators found that use of NSAIDs for more 6 months reduced the risk of glioma by 50% (OR = 0.5, 95% CI 0.4, 0.7).

Further Steps

Confirming these findings, as well as determining how these medications might be chemopreventive and which individuals might benefit from their use requires additional research efforts. Dr. Lai et al. plan to explore whether genetic polymorphisms of genes in the HMGCoA reductase pathway, Rho and Ras GTPases, may be modifying factors for statin therapy. Eventually, their investigation strategy may lead to the selection of those individuals with the right genetic profiles as chemoprevention candidates.

Disclaimer

The information and opinions expressed herein are those of the participants and do not necessarily reflect those of Xfacto Communications Inc. or the sponsor. The distribution of this meeting report was made possible through industry support under written agreement that ensures editorial independence. The content is for educational purposes and should not be taken as an endorsement of any products, uses or doses. Physicians should consult the appropriate monograph before prescribing any drugs. Distribution, reproduction, alteration of this program is strictly prohibited without written consent of Xfacto Communications Inc. Copyright 2020. All rights reserved. The Medical XchangeTM

This web site is solely for healthcare professionals

Yes, I am a healthcare professional No, I am not a healthcare professional
×
New user?
×
Sign up for the Medical Xchange Here you'll find expert commentary from the most recent medical meetings around the world, as well as features and interviews with top healthcare professionals.
First name* Last name*
Title Gender*
Email* Confirm Email*
Password* Password must have at least 8 characters with at least one Capital letter, one lower case letter and one number or special character Confirm Password*
Profession* Speciality*
Country* Province*